JAMA Oncol 2020 Aug 13
Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer: A Phase 3 Randomized Clinical Trial.
Abstract
Importance
The value of platinum-based adjuvant chemotherapy in patients with triple-negative breast cancer (TNBC) remains controversial, as does whether BRCA1 and BRCA2 (BRCA1/2) germline variants are associated with platinum treatment sensitivity.
Objective
To compare 6 cycles of paclitaxel plus carboplatin (PCb) with a standard-dose regimen of 3 cycles of cyclophosphamide, epirubicin, and fluorouracil followed by 3 cycles of docetaxel (CEF-T).
Design, setting, and participants
This phase 3 randomized clinical trial was conducted at 9 cancer centers and hospitals in China. Between July 1, 2011, and April 30, 2016, women aged 18 to 70 years with operable TNBC after definitive surgery (having pathologically confirmed regional node-positive disease or node-negative disease with tumor diameter >10 mm) were screened and enrolled. Exclusion criteria included having metastatic or locally advanced disease, having non-TNBC, or receiving preoperative anticancer therapy. Data were analyzed from December 1, 2019, to January 31, 2020, from the intent-to-treat population as prespecified in the protocol.
Interventions
Participants were randomized to receive PCb (paclitaxel 80 mg/m2 and carboplatin [area under the curve = 2] on days 1, 8, and 15 every 28 days for 6 cycles) or CEF-T (cyclophosphamide 500 mg/m2, epirubicin 100 mg/m2, and fluorouracil 500 mg/m2 every 3 weeks for 3 cycles followed by docetaxel 100 mg/m2 every 3 weeks for 3 cycles).
Main outcomes and measures
The primary end point was disease-free survival (DFS). Secondary end points included overall survival, distant DFS, relapse-free survival, DFS in patients with germline variants in BRCA1/2 or homologous recombination repair (HRR)-related genes, and toxicity.
Results
A total of 647 patients (mean [SD] age, 51 [44-57] years) with operable TNBC were randomized to receive CEF-T (n = 322) or PCb (n = 325). At a median follow-up of 62 months, DFS time was longer in those assigned to PCb compared with CEF-T (5-year DFS, 86.5% vs 80.3%, hazard ratio [HR] = 0.65; 95% CI, 0.44-0.96; P = .03). Similar outcomes were observed for distant DFS and relapse-free survival. There was no statistically significant difference in overall survival between the groups (HR = 0.71; 95% CI, 0.42-1.22, P = .22). In the exploratory and hypothesis-generating subgroup analyses of PCb vs CEF-T, the HR for DFS was 0.44 (95% CI, 0.15-1.31; P = .14) in patients with the BRCA1/2 variant and 0.39 (95% CI, 0.15-0.99; P = .04) in those with the HRR variant. Safety data were consistent with the known safety profiles of relevant drugs.
Conclusions and relevance
These findings suggest that a paclitaxel-plus-carboplatin regimen is an effective alternative adjuvant chemotherapy choice for patients with operable TNBC. In the era of molecular classification, subsets of TNBC sensitive to PCb should be further investigated.
Trial registration
ClinicalTrials.gov Identifier: NCT01216111.
Related Questions
How would you approach treatment for a patient in the early third trimester of pregnancy who is newly diagnosed with cT2N0 triple-negative breast cancer (TNBC)?
Since the patient is in her third trimester, chemotherapy administration should be safe. We do not have a lot of safety data for the use of pembrolizumab in pregnant women. However, exposing a pregnant woman to an immune checkpoint inhibitor carries at least a theoretical concern that it may disrupt...
How would you approach the treatment of low grade, stage IA, triple negative apocrine adenocarcinoma of the breast in a female patient in her 70s?
I would not treat this the way I would a typical triple-negative breast cancer, since the risk of distant recurrence from occult metastatic disease is low. Assuming she had breast-conserving surgery, radiation, favoring partial breast, is reasonable. In terms of systemic therapy, if the cancer in th...
What adjuvant therapy would you recommend for a premenopausal woman with low ER+/PR+ (1-10%) HER2- pT1cN0 metaplastic breast cancer?
The rarity of the metaplastic subtype of breast cancer makes it difficult to provide an evidence-based answer regarding what is the "best" adjuvant treatment. About 70% of metaplastic tumors are TNBC and ER-low is a small subset of the remaining 20% with an ER+ epithelial component. In general, some...
How would you approach radiation for an elderly patient with pT2N1 TNBC s/p MRM and ALND who refused chemo-immunotherapy?
RT will offer improved local control in this patient, as she has an elevated risk of LRR (positive LN, triple negative, large-ish T2, grade 3, LVSI). It will be unlikely to change her survival, as the data for PMRT did not show survival benefit until the chemotherapy was good enough to decrease dis...
Do you start systemic therapy for patients with previously localized HR+ breast cancer developing solitary bone metastasis which is now triple negative if there are no other sites of disease after metastasis-directed radiation?
I would start chemotherapy because of the triple-negative status of the metastasis. This is a patient who initially presented with hormone receptor-positive breast cancer and subsequently developed an isolated bone metastasis that was triple negative. The question of systemic therapy post-localized ...
How do you interpret the EBCTCG meta-analysis analyzing the magnitude of benefit of anthracyclines in early stage ER+ breast cancer?
The appreciation of studies testing the specific benefit of adding or substituting anthracyclines as adjuvant therapy for early stage breast cancer requires a historical overview (so my apologies for a very long response….). Several of the earlier trials comparing non-anthracycline therapies (primar...
Would you consider using anthracycline for treating a Stage I triple negative breast cancer in a patient with a baseline mildly reduced LVEF 50-55%?
I'm going to assume this is the clinical stage, and the patient has not yet had surgery. In this arena, if the patient is a fit surgical candidate then there are those who might advocate for taking to surgery up front if they are otherwise healthy. In patients like this, you could have a look at the...
Would you consider omitting platinum from neoadjuvant chemotherapy in women > 50 years of age with localized triple negative breast cancer?
I would not use the results cited above from the >50 subgroup (which was just 30% of their study population) of the study from the Tata Memorial Centre to justify omission of carboplatin from the neoadjuvant regimen for TNBC in otherwise healthy patients over 50 with TNBC. There is compelling data f...
What adjuvant chemotherapy regimen do you recommend for a patient with T1cN0 TNBC?
This is such a nuanced question that comes up with our fellows and affiliates a lot. I will give my take on this, although I want to acknowledge there are still pockets of uncertainty here!I want to start by saying that in the purely adjuvant setting, we have the ABC trials (USOR 06-090, NSABP-B46I/...
What would be your regimen of choice for a healthy 80+ year old with localized triple negative breast cancer?
My inclination would be to avoid administering an anthracycline to such a patient, as long as you include a taxane and carboplatin in her treatment regimen. If you're treating her in the neoadjuvant setting, Sharma and colleagues achieved a similar pCR rate with every 3-week docetaxel and carboplati...
Which neoadjuvant chemotherapy regimen would you use in a young, premenopausal woman with a rapidly growing clinical node positive poorly differentiated TNBC with a germline PALB2 mutation?
My preference is 2) weekly paclitaxel/carboplatin followed by AC, with adjuvant capecitabine if residual disease. There is no doubt that the addition of carboplatin increases the pCR rate in TNBC, and data from GeparSixto and patients on CALGB 40603 in whom doses of paclitaxel/carboplatin were not o...
How do you approach using non-anthracycline based neoadjuvant treatment for triple negative breast cancer, especially in older patients with node negative disease?
There is compelling data that including carboplatin in neoadjuvant therapy for TNBC significantly increases pCR rates, and may allow omission of an anthracycline without compromising long-term outcomes. Until very recently, my anthracycline-free neoadjuvant regimen of choice was every 3-weeks doceta...
How would you approach an elderly patient with early stage TNBC with node negative disease?
While patient age, comorbidities, and T stage could influence my recommendations, if I felt that the patient was in good enough shape to tolerate chemotherapy and that her risk of distant recurrence was high enough to warrant treatment (relative to her life expectancy), I would favor administering w...
Is there any data available regarding the benefit of adjuvant chemotherapy in patients with early stage, lymph node negative, triple negative adenosquamous breast cancers?
Except for a rare low-grade adenosquamous carcinoma, which, according to UpToDate (Taqhian A, Merajver S. Overview of the treatment of newly diagnosed, non-metastatic breast cancer - Rare histologies — Certain very rare subtypes of metaplastic carcinoma (eg, low-grade adenosquamous and low-grade fib...